Serum and Synovial Fluid Concentrations of Matrix Metalloproteinases 3 and Its Tissue Inhibitor 1 in Juvenile Idiopathic Arthritisides

MARCO GATTORNO, SILVIA VIGNOLA, FERNANDA FALCINI, FEDERICA SABATINI, ANTONELLA BUONCOMPAGNI, GABRIELE SIMONINI, PAOLO PICCO, and VITO PISTOIA

ABSTRACT. Objective. Matrix metalloproteinases (MMP) are a large family of proteolytic enzymes involved in the remodeling of extracellular matrix during tissue resorption in idiopathic arthritides. We investigated serum and synovial fluid (SF) concentrations of MMP-3 and its tissue inhibitor (TIMP-1) in juvenile idiopathic arthritides (JIA).

Methods. Sera from 45 patients with active, 15 patients with inactive JIA, and 15 healthy controls were evaluated by ELISA for MMP-3 (stromelysin-1), TIMP-1, and soluble p75 tumor necrosis factor receptor (sTNFR). Paired SF concentrations were evaluated in 19 patients with JIA.

Results. MMP-3 serum concentrations were significantly higher in patients with active poly- and oligoarticular JIA versus inactive patients (p = 0.04 and p = 0.02, respectively) and healthy controls (p < 0.001 for both). Serum MMP-3, but not TIMP-1, concentration displayed a variable degree of correlation with clinical and laboratory variables of disease activity and with p75 sTNFR concentrations (r = 0.37, p = 0.005). SF MMP-3 concentrations were 30–300 times higher than those found in paired sera (p < 0.001, Wilcoxon rank test). A clear inversion of MMP-3/TIMP-1 ratio was observed when sera (median 0.31, range 0.02–1.5) were compared with the corresponding SF samples (5.3, range 4.9–5.5; p < 0.001).

Conclusion. MMP-3 (stromelysin-1) is clearly overexpressed in SF of patients with JIA. An inadequate counter-expression of TIMP-1 may represent a crucial event for the development and perpetuation of tissue damage. (J Rheumatol 2002;29:826–31)

Key Indexing Terms: JUVENILE IDIOPATHIC ARTHRITIS MATRIX METALLOPROTEINASES

In idiopathic inflammatory arthritides, proliferating synovial membrane plays a pivotal role in cartilage and bone destruction. In these disorders, macrophages and fibroblast-like cells are the major component of the lining layer of the synovial tissue, especially at the level of the cartilage-pannus junction. Both cell types produce proinflammatory cytokines, growth factors, chemokines, and degrading enzymes, all of which cause and perpetuate tissue damage.

The role played by proteolytic enzymes, such as collagenases, in the pathogenesis of rheumatoid synovitis was described over 30 years ago. Matrix metalloproteinases (MMP) are a large family of proteolytic enzymes acting in both physiological conditions (e.g., embryonic development, organ morphogenesis, angiogenesis) and pathological conditions (e.g., chronic inflammatory diseases, tumors).

In adult rheumatoid arthritis (RA), MMP are thought to play a pivotal role in matrix remodeling and cartilage and bone destruction. Overexpression of a number of MMP (mainly MMP-3 and MMP-1) has been reported both at the level of lining and sublining layers of rheumatoid synovial tissue and in biological fluids, such as plasma and synovial fluid.

Together with other proinflammatory cytokines and growth factors, tumor necrosis factor (TNF-α) plays an important role in the regulation of the expression of many MMP by synovial synoviocytes.

Four different natural inhibitors of MMP, namely, tissue inhibitor of metalloproteinase-1 (TIMP-1 to TIMP-4), interact with activated MMP, forming a 1:1 stoichiometric complex. TIMP-1 is the most abundantly expressed natural MMP inhibitor in the lining cells of adult rheumatoid synovium and has also been detected in both sera and SF from patients with RA.

We investigated the serum and SF concentrations of MMP-3 and TIMP-1 in juvenile idiopathic arthritis (JIA) and their relationships with TNF-α involvement.
RESULTS

The clinical characteristics of selected patients with JIA at the time of study are reported in Table 1. A total of 45 sera obtained during the active phase of disease were evaluated. As stated, at the time of study, 15 patients displayed a polyarticular course (4 systemic onset, 3 RF negative polyarticular onset, 8 extended oligoarticular course), whereas 30 patients displayed a persistent oligoarticular course. At the time of serum sampling 21/30 patients with persistent oligoarticular disease were positive for antinuclear antibodies. The ongoing treatment at the time of study is reported in Table 1. Among active patients, 16 were treated with nonsteroidal antiinflammatory drugs (NSAID) alone (Group A), 12 a combination of NSAID and methotrexate (MTX) (Group B), and 8 with NSAID and oral steroids (Group C).

Fifteen sera from patients with persistent oligoarticular course and clinical evidence of disease inactivity were also studied (Table 1). In these patients, the mean duration of disease inactivity at the time of study was 5.1 months (range 0.5–23).

MMP-3 serum concentrations were significantly higher in patients with active JIA with polyarticular course (median 213.2 ng/ml, range 18.2–490) and JIA with active oligoarticular course (64 ng/ml, 10.2–610) than in inactive oligoarticular JIA (17.6 ng/ml, 2.4–88; p = 0.04 and p = 0.02, respectively) or healthy controls (2.4 ng/ml, 0–46; p < 0.001 for both; Figure 1A).

TIMP-1 serum concentrations were significantly higher in patients with active polyarticular (median 898.7 ng/ml, range 802–943) and oligoarticular JIA (871 ng/ml, 616–979) than in healthy controls (453.2 ng/ml, 322–752; p = 0.03 and p = 0.01, respectively). Conversely, inactive oligoarticular JIA patients showed significantly higher TIMP-1 concentrations (948 ng/ml, 440–968) than patients with active polyarticular (p = 0.01) or oligoarticular JIA (p = 0.004) (Figure 1B).

Notably, within JIA patients with a polyarticular course, no differences were noted for MMP-3 and TIMP-1 concentrations among patients with systemic onset (median MMP-3: 158.4 ng/ml, range 18.8–469; median TIMP-1: 887.2 ng/ml, 856–906), RF negative polyarticular onset (MMP-3: 253 ng/ml, 190–236; TIMP-1: 900 ng/ml, 896–908), and extended oligoarticular form (MMP-3: 215 ng/ml, 41–425; TIMP-1: 852 ng/ml, 748–911).

When the behavior of the serum MMP-3/TIMP-1 ratio in the 4 subgroups was considered, a significantly higher ratio was found in active polyarticular JIA patients than in inactive oligoarticular JIA patients (p = 0.03) and healthy controls (p = 0.02). Conversely, no statistically significant difference was observed between active oligoarticular patients and inactive oligoarticular patients (p = 0.24) or healthy controls (p = 0.18) (Figure 2A).

SF MMP-3 concentrations (median 4868 ng/ml, range
3972–4964.4) were 3–300 times higher than those detected in paired sera (median 213 ng/ml, range 10.1–1350; p < 0.001, Wilcoxon rank test). Moreover, SF TIMP-1 concentrations (917 ng/ml, 886.4–980 ng/ml) were significantly higher than those detected in paired serum samples (775 ng/ml, 569.6–928; p = 0.02) (data not shown). Notably, a clear inversion of the MMP-3/TIMP-1 ratio was observed when sera ratios (median 0.31, 0.02–1.5) were compared with the correspondent SF values (5.3, range 4.9–5.5; p < 0.001, Wilcoxon rank test; Figure 2B).

Taking into account the difference in the molecular weight between MMP-3 (57 kDa) and TIMP-1 (28 kDa), serum and SF concentrations were reconverted to be expressed as µmol/ml. Median MMP-3 molar concentrations were 85.4 µmol/ml (range 69.6–87) in SF and 3.7 µmol/ml (range 0.1–23.6) in paired sera. Median TIMP-1 SF molar concentration was 32.1 µmol/ml (range 31.1–34.3), whereas corresponding serum concentrations were 27.1 µmol/ml (range 19.9–32.5) (data not shown). Thus in SF, MMP-3 displayed a 2.6-fold molar excess versus corresponding TIMP-1. Conversely, in sera, TIMP-1 displayed a 7.3-fold molar excess versus MMP-3.

MMP-3 serum concentrations displayed a significant

Figure 1. Differences in MMP-3 (A) and TIMP-1 (B) serum concentrations among the 3 subgroups of JIA patients and healthy controls. Horizontal lines represent median values in each study group. A. MMP-3 serum concentrations were significantly higher in active polyarticular and active oligoarticular patients than in inactive oligoarticular patients (p = 0.04 and p = 0.02, respectively) or healthy controls (p < 0.001 for both). B. TIMP-1 serum concentrations were significantly higher in active polyarticular and oligoarticular patients than in healthy controls (p = 0.03 and p = 0.01, respectively). Conversely, inactive oligoarticular patients showed higher TIMP-1 concentrations than active polyarticular (p = 0.01) or oligoarticular (p = 0.004) patients.

Table 1. Clinical and laboratory features of patients with JIA at the time of study.

<table>
<thead>
<tr>
<th></th>
<th>Age, mean (range), yrs</th>
<th>Disease duration, yrs</th>
<th>No. of joints Active/Limited ROM</th>
<th>PGI</th>
<th>ESR</th>
<th>Treatment [pts]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyarticular</td>
<td>7.2 (3.3–16.1)</td>
<td>3.7 (0.5–11.2)</td>
<td>7/12.2 (1–16)/(1–29)</td>
<td>8.8</td>
<td>7 (10)</td>
<td>NSAID, MTX [8]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID, CS, MTX [3]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID, CS [2]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID alone [2]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID alone [14]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID, CS [6]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID, MTX [4]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nil [6]</td>
</tr>
<tr>
<td>Oligoarticular</td>
<td>8.5 (3–17.9)</td>
<td>2.4 (0.3–14)</td>
<td>1.3/1.5 (1–3)/(1–3)</td>
<td>6.9</td>
<td>6 (10)</td>
<td>35.5 (7–104)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID alone [14]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID, CS [6]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSAID, MTX [4]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nil [6]</td>
</tr>
<tr>
<td>Inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oligoarticular</td>
<td>7.3 (3.8–15)</td>
<td>3.4 (0.9–15)</td>
<td>0/0</td>
<td>0</td>
<td>13.5 (2–20)</td>
<td>NSAID alone [6]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTX, NSAID [1]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nil [8]</td>
</tr>
</tbody>
</table>

ROM: range of motion; PGI: physician global index; ESR: erythrocyte sedimentation rate; NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate; CS: corticosteroids.

www.jrheum.org
correlation with a number of clinical and laboratory disease activity variables and with p75 sTNFR (Table 2), whereas TIMP-1 serum concentration did not (Table 2). No significant correlation was found between MMP-3 and TIMP-1 serum and SF concentrations. In SF, both MMP-3 and TIMP-1 showed a clear correlation with p75 sTNFR ($r = 0.43$, $p = 0.0001^*$ $r = 0.61$, $p = 0.0001^*$, respectively; data not shown).

The possible influence of MTX or steroid treatment on MMP-3 and TIMP-1 serum concentration was evaluated using a multivariable ANOVA model correcting for disease activity (number of active joints, physician global estimate of disease activity, ESR). No significant differences among Group A (NSAID treatment alone), Group B (NSAID plus MTX), or Group C (NSAID plus corticosteroids) were noted (data not shown).

**DISCUSSION**

MMP are a large family of zinc dependent endoproteases that degrade most extracellular matrix components. All MMP are synthesized as proenzymes by a wide range of cell types. Their expression is transcriptionally regulated by different growth factors (e.g., platelet derived growth factor, fibroblast growth factor), proinflammatory cytokines (mainly TNF-α and interleukin 1), and hormones (insulin-like growth factor I, prolactin). Inactive pro-MMP are secreted and subsequently activated in vivo by tissue or plasma proteinases through the proteolytic cleavage of the propeptide domain.

The biological activity of all MMP is inhibited in vivo by 4 specific endogenous tissue inhibitors called TIMP. TIMP control connective tissue breakdown both by blocking the action of the activated MMP and by preventing their activation. In physiological conditions, TIMP levels exceed those of active MMP. In vitro and in vivo studies have shown that TIMP can also inhibit cell invasion, tumorigenesis, and neoangiogenesis mediated by MMP. TIMP are expressed by the same cells that produce MMP, mainly upon stimulation with proinflammatory cytokines.

To our knowledge, no information is yet available on MMP and TIMP concentrations in SF of patients with JIA. In this study, the concomitant evaluation of MMP-3 in sera and SF showed a clear overexpression of this protease at the site of chronic inflammation, with SF concentrations 3 to 300 times higher than in paired serum samples. Further, taking into account the clear molar excess of MMP-3 versus corresponding TIMP-1, it is possible that there is inadequate SF production of this major MMP natural inhibitor. It is notable that TIMP bind to MMP to form a tight ($K_i < 1$ nm) 1:1 stoichiometric noncovalent complex.

Although MMP-3 and TIMP-1 mRNA coexpression was detected in intimal lining cells from RA patients, impaired TIMP-1 protein production has been reported in studies of
RA, at the level of both SF and tissue\textsuperscript{11,17,32,33}. This latter issue has been recently confirmed also on synovial tissue of patients with JIA (Gattorno, \textit{et al}, unpublished results).

According to Burger and coworkers, a possible explanation for these observations may be found in a different modulation of MMP and TIMP production by synoviocytes after cell–cell contact with activated T lymphocytes\textsuperscript{34}.

MMP-3 serum concentrations were found to be significantly higher in patients with active versus those with inactive JIA, or in healthy controls. These findings are in accord with conclusions of studies in RA\textsuperscript{16-18} and a serological study in JIA\textsuperscript{35}. Moreover, serum MMP-3 were found to positively correlate with a number of clinical and laboratory variables of disease activity\textsuperscript{36,37}.

The investigation of the influence of treatment on MMP production was not a goal of the present study. Due to the wide range of disease subtypes and treatments this question was particularly difficult to investigate in a retrospective study. However, the use of a multivariate analysis correcting for the degree of disease activity allowed us to grossly exclude the presence of a clear influence of treatment on MMP-3 and TIMP-1 production, as shown in RA for MTX\textsuperscript{29}. Notably, MMP serum levels may also be significantly influenced by individual patient physical activity before sampling\textsuperscript{38}. This particular issue may explain the relative degree of variability of MMP-3 serum concentration we found in patients with active JIA.

In relatively recent inactive patients with the persistent oligoarticular form, serum TIMP-1 concentrations were significantly higher than in active persistent oligoarticular patients. This finding is consistent with a previous observation in RA patients showing significantly higher TIMP-1 concentrations in patients with mild or moderate functional disability than in patients with severe disability\textsuperscript{39}.

An additional feature coming from the study concerns the possible functional interaction between MMP-3 and TIMP-1 and proinflammatory cytokines, such as TNF-\(\alpha\). Together with other proinflammatory cytokines and growth factors, TNF-\(\alpha\) plays an important role in regulation of the expression of both MMP and TIMP\textsuperscript{19,40}. Conversely, the proteolytic activities of some MMP (mainly MMP-3 and MMP-13) have been shown to be crucial for the functional activation of proinflammatory cytokines. TNF-\(\alpha\), for example, is initially expressed as a 233 amino acid membrane anchored precursor that is proteolytically processed by MMP to yield the functional 157 amino acid cytokine\textsuperscript{41}. In this study, a significant and strong correlation between sTNFp75 and MMP-3 levels was found, suggesting the existence of mutual functional relationships between TNF and MMP. Interestingly, synthetic MMP inhibitors can decrease \textit{in vitro} membrane TNF-\(\alpha\) release by many cell types\textsuperscript{42}.

These observations may provide additional support to the development of an anti-MMP strategy for treatment of idiopathic inflammatory arthritides\textsuperscript{43,44}.

\textbf{ACKNOWLEDGMENT}

We thank Dr. Maria Pia Sormani for her valuable suggestions for statistical analysis.

\textbf{REFERENCES}

18. Ishiguro N, Ito T, Miyazaki K, Iwata H. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in
33. Jackson CJ, Arkell J, Oberhoff R, Reinke H, TschescHE H. Isolation and characterization of tissue inhibitors of metallopro-
teinases (TIMP-1 and TIMP-2) from human rheumatoid syno-
32. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM,
Ravelli A, Migliavacca D, et al. Responsiveness of
rheumatoid arthritis patients responding to methotrexate treatment.
31. Cawston TE, Murphy G, Mercer E, Galloway WA, Hazleman BL,
Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL.
Immunolocalisation studies on six matrix metalloproteinases and
their inhibitors, TIMP-1 and TIMP-2, in synova from patients with osteo-
29. Seitz M, Dayer JM. Enhanced production of tissue inhibitor of metallopro-
teinases-1 (TIMP-1), and TIMP-2 in synovial fluid from patients with rheumatoid arthritis.
28. Cope AP, Maini RM. Soluble tumor necrosis factor receptors in
27. Cope AP, Maini RM. Soluble tumor necrosis factor receptors in
metalloproteinase may contribute to cartilage degradation in
A. Preliminary definition of improvement in juvenile arthritis.
A. Preliminary definition of improvement in juvenile arthritis.
23. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed
classification criteria for juvenile idiopathic arthritis: Durban, 1997.
22. Mercer E, Cawston TE, de Silva M, Hazleman BL. Purification of a
metalloproteinase inhibitor from human rheumatoid synovial fluid.
21. Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL.
Immunolocalisation studies on six matrix metalloproteinases and
their inhibitors, TIMP-1 and TIMP-2, in synova from patients with osteo-
Isolation and characterization of tissue inhibitors of metallopro-
teinases (TIMP-1 and TIMP-2) from human rheumatoid syno-
of monocyte matrix metalloproteinase and TIMP-1 production by
TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through
prostaglandin-dependent and -independent mechanisms. J Immunol